TY - JOUR
T1 - Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease
AU - Machida, Toshiya
AU - Obara, Taku
AU - Miyazaki, Makoto
AU - Inoue, Jun
AU - Mano, Nariyasu
N1 - Funding Information:
The authors would like to thank JMIRI, Inc. who provided the claims database.
Publisher Copyright:
© 2022 Fundación Clínica Médica Sur, A.C.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - Introduction and objectives: Clinical guidelines recommend specific drugs for type 2 diabetes (T2D), hypertension, and dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). We aimed to investigate the differences in prescription trends of antidiabetic, antihypertensive, and lipid-lowering drugs among adult patients according to the presence of comorbid NAFLD and/or NASH. Methods: We conducted a cross-sectional analysis using a large claims database from January 2013 to December 2020. Results: Among 7,716,908 people, 47,157 patients with T2D, 180,050 with hypertension, and 191,348 with dyslipidemia were identified. A total of 8,897, 16,451, and 24,762 patients with NAFLD, as well as 435, 523, and 1033 patients with NASH, had T2D, hypertension, and dyslipidemia, respectively. Among antidiabetic drugs, sodium–glucose cotransporter-2 inhibitors (SGLT2is) and thiazolidine were more frequently prescribed to patients with NAFLD than to those without NAFLD (non-NAFLD) (thiazolidine: 1.4% and 2.8% and SGLT2is: 17.8% and 25.9% for non-NAFLD and NAFLD, respectively [2019–2020]). Among antihypertensive drugs, angiotensin II receptor antagonists exhibited a slightly higher prescription ratio in patients with NAFLD (33.6% vs. 39.0%). Regarding lipid-lowering drugs, fibrates were more frequently prescribed to patients with NAFLD (10.3% vs. 18.4%). Conclusions: Specific drugs tended to be prescribed to patients with NAFLD. However, the differences in prescription ratios were not considerable. Further investigation is required to confirm the effects of drugs on the prognosis of patients with NAFLD or NASH.
AB - Introduction and objectives: Clinical guidelines recommend specific drugs for type 2 diabetes (T2D), hypertension, and dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). We aimed to investigate the differences in prescription trends of antidiabetic, antihypertensive, and lipid-lowering drugs among adult patients according to the presence of comorbid NAFLD and/or NASH. Methods: We conducted a cross-sectional analysis using a large claims database from January 2013 to December 2020. Results: Among 7,716,908 people, 47,157 patients with T2D, 180,050 with hypertension, and 191,348 with dyslipidemia were identified. A total of 8,897, 16,451, and 24,762 patients with NAFLD, as well as 435, 523, and 1033 patients with NASH, had T2D, hypertension, and dyslipidemia, respectively. Among antidiabetic drugs, sodium–glucose cotransporter-2 inhibitors (SGLT2is) and thiazolidine were more frequently prescribed to patients with NAFLD than to those without NAFLD (non-NAFLD) (thiazolidine: 1.4% and 2.8% and SGLT2is: 17.8% and 25.9% for non-NAFLD and NAFLD, respectively [2019–2020]). Among antihypertensive drugs, angiotensin II receptor antagonists exhibited a slightly higher prescription ratio in patients with NAFLD (33.6% vs. 39.0%). Regarding lipid-lowering drugs, fibrates were more frequently prescribed to patients with NAFLD (10.3% vs. 18.4%). Conclusions: Specific drugs tended to be prescribed to patients with NAFLD. However, the differences in prescription ratios were not considerable. Further investigation is required to confirm the effects of drugs on the prognosis of patients with NAFLD or NASH.
KW - Antidiabetic drug
KW - Antihypertensive drug
KW - Clinical guideline
KW - Lipid-lowering drug
KW - Non-alcoholic fatty liver disease
KW - Non-alcoholic steatohepatitis
UR - http://www.scopus.com/inward/record.url?scp=85126903486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126903486&partnerID=8YFLogxK
U2 - 10.1016/j.aohep.2022.100699
DO - 10.1016/j.aohep.2022.100699
M3 - Article
C2 - 35278680
AN - SCOPUS:85126903486
SN - 1665-2681
VL - 27
JO - Annals of Hepatology
JF - Annals of Hepatology
IS - 4
M1 - 100699
ER -
